Athlete Perceptions of Flavored, Menthol-enhanced Energy Gels Ingested Prior to Running in the Heat

Thermal perception during exercise is known to influence endurance performance and the onset of fatigue. L-menthol, an organic compound derived from peppermint, evokes a cooling sensation through its action on TRPM8 channels which also respond to cold stimuli. Recent work identified that the internal application of menthol-enhanced fluids can be ergogenic during exercise in the heat. Hence, the addition of menthol to energy gels may be practical and beneficial for athletes. PURPOSE: To determine athlete acceptability and preferences for flavored energy gels with different menthol concentrations. METHODS: With a randomized, crossover, and double-blind placebo-controlled design, 27 endurance athletes (34.8±6.7 y, BMI: 21.7±1.6 kg·m-2, 9 female) ingested an energy gel with a menthol additive at relative concentrations: low (0.1%), medium-low (0.3%), medium-high (0.5%), high (0.7%), or a non-menthol, flavor-matched placebo (CON), on separate days before outdoor running sessions. Athletes rated the gels for cooling sensation, irritation (tingling/burning), flavor, and overall experience on 100-point sensory and hedonic labeled magnitude scales. The duration of any cooling sensation was also reported. Repeated measures ANOVAs with a Bonferroni adjustment for pairwise comparisons were used to determine differences. RESULTS: All menthol gels successfully delivered a greater cooling sensation compared to CON (7.4±8.1 AU) with a significantly greater response for 0.7% (59.9±20.5 AU) and 0.5% (57.7±21.8 AU), compared to all others, which were both rated “moderate-strong” for intensity. Irritation intensity was higher for all menthol gels compared to CON (3.4±7.2 AU), and for 0.7% compared to 0.1% (31.1±31.0 vs 16.3±21.0 AU, p=0.041), with none reported higher than a “mild-moderate” intensity. The menthol gels delivered a significantly longer cooling duration (range: 12.3-19.6 min) compared to CON (2.2±4.8 min) with no significant difference between menthol gels. Ratings of overall experience and flavor were not different between gels (p\u3e.05). CONCLUSION: A flavored energy gel with the addition of menthol at 0.1-0.7% provides a cooling sensation for athletes when ingested before exercise. The 0.5% concentration is recommended to maximize the cooling sensation of the gel whilst minimizing irritation

The return to 1980 stratospheric halogen levels: A moving target in ozone assessments from 2006 to 2022

The international scientific assessment of ozone depletion is prepared every four years to support decisions made by the Parties to the Montreal Protocol. In each assessment an outlook of ozone recovery time is provided. The year when equivalent effective stratospheric chlorine (EESC) returns to the level found in 1980 is an important metric for the recovery of the ozone layer. Over the past five assessments, the expected date for the return of EESC to the 1980 level, for mid-latitudes, has been delayed, from year 2049 in the 2006 assessment to 2066 in the 2022 assessment, which represents a delay of 17 years over a 16-year assessment period. Here, we quantify the primary drivers that have delayed the expected EESC recovery date between each of these assessments. We find that by using identical EESC formulations the delay between the 2006 and 2022 assessment’s expected return of EESC to 1980 levels is shortened to 12.6 years. Of this delay, bank calculation methods account for ~4 years, changes in the assumed atmospheric lifetime for certain ODSs account for ~3.5 years, an under-estimate of the emission of CCl4 accounts for ~3 years, and updated historical mole fraction estimates of ODSs account for ~1 year. Since some of the underlying causes of these delays are amenable to future controls (e.g. capture of ODSs from banks and limitations on future feedstock emissions), it is important to understand the reasons for the delays in expected recovery date of stratospheric halogens

Athlete perceptions of flavored, menthol-enhanced energy gels ingested prior to endurance exercise in the heat

Background L-menthol evokes a cooling sensation by activating cold sensing cation channels. Menthol-enhanced fluids can be ergogenic during exercise in the heat by improving thermal perception; hence, the addition of menthol to energy gels may benefit athletes. Previously, unflavored menthol gels were deemed acceptable at 0.1% concentration, but no research has been undertaken on menthol gels with additional flavoring. Therefore, we determined athlete perceptions of flavored energy gels with different menthol concentrations. Methods With a randomized, crossover, double-blind, placebo-controlled design, 27 athletes (34.8 ± 6.7 y, 9 females) ingested an energy gel with either 0.1%, 0.3%, 0.5%, or 0.7% menthol concentration, or a non-menthol, flavor-matched placebo (CON), on separate occasions before outdoor exercise. Gels were rated for cooling sensation, irritation, flavor, and overall experience on 100-point sensory and hedonic labeled magnitude scales. The duration of any cooling sensation was also reported. Results All menthol gels delivered a greater cooling sensation compared to CON (7.4 ± 8.1 AU) with a significantly greater response for 0.7% (59.9 ± 20.5 AU) and 0.5% (57.7 ± 21.8 AU), compared to all others. Irritation was higher for all menthol gels compared to CON (3.4 ± 7.2 AU) and for 0.7% compared to 0.1% (31.1 ± 31.0 vs. 16.3 ± 21.0 AU, p = 0.041), with none rated above a ‘mild-moderate’ intensity. The menthol gels delivered a significantly longer cooling sensation duration (12.3-19.6 min) versus CON (2.2 ± 4.8 min) with no difference between menthol gels. Conclusion A flavored menthol energy gel at 0.1–0.7% concentration provides a cooling sensation for athletes when ingested before exercise. The 0.5% concentration is recommended to maximize the cooling sensation whilst minimizing irritation

A menthol-enhanced “cooling” energy gel does not influence laboratory time trial performance in trained runners

l-menthol (menthol) is an organic compound derived from peppermint which imparts a refreshing mint flavor and aroma to oral hygiene products, chewing gum, and topical analgesics. Menthol has been identified as a non-thermal sensory cooling strategy for athletes when ingested or mouth-rinsed during exercise in hot environments. Therefore, sports nutrition products delivering a controlled concentration of menthol could be beneficial for athletes exercising in the heat. We sought to test the performance and perceptual outcomes of a novel menthol energy gel during treadmill running in the heat (33 °C, 49% RH). Fourteen trained runners (mean ± SD; age: 31 ± 6 years, VO2max: 56.5 ± 10.1 mL·kg−1·min−1, BMI: 23.2 ± 2.4 kg/m2; six female) participated in a randomized, crossover, double-blind, and placebo-controlled study. A menthol-enhanced energy gel (0.5% concentration; MEN) or flavor-matched placebo (PLA) was ingested 5 min before and again at 20 and 40 min of a 40 min treadmill exercise preload at 60% VO2max, followed by a 20 min self-paced time trial. The total distance, vertical distance, perceptual measures (thermal comfort, thermal sensation, rating of perceived exertion, and affect), and cognitive performance via computerized neurocognitive assessment were measured. No difference between 20 min self-paced time trial total distance (MEN: 4.22 ± 0.54 km, PLA: 4.22 ± 0.55 km, p = 0.867), vertical distance (MEN: 49.2 ± 24.6 m, PLA: 44.4 ± 11.4 m, p = 0.516), or any perceptual measures was observed (all p > 0.05). Cognitive performance was not different between the trials (all p > 0.05). These results suggest that a menthol energy gel is not superior to a non-menthol gel in terms of performance or perception during treadmill running in the heat. More research is needed to confirm whether these findings translate to ecologically valid settings, including outdoor exercise in ambient heat and during competition

Black hole growth and host galaxy morphology

We use data from large surveys of the local Universe (SDSS+Galaxy Zoo) to show that the galaxy-black hole connection is linked to host morphology at a fundamental level. The fraction of early-type galaxies with actively growing black holes, and therefore the AGN duty cycle, declines significantly with increasing black hole mass. Late-type galaxies exhibit the opposite trend: the fraction of actively growing black holes increases with black hole mass.Comment: 4 pages, 2 figures. Proceedings of the IAU Symposium no. 267, "Co-Evolution of Central Black Holes and Galaxies: Feeding and Feedback", eds. B.M. Peterson, R.S. Somerville and T. Storchi-Bergman

Screen time and early adolescent mental health, academic, and social outcomes in 9-and 10-year old children: Utilizing the Adolescent Brain Cognitive Development (SM) (ABCD) Study

In a technology-driven society, screens are being used more than ever. The high rate of electronic media use among children and adolescents begs the question: is screen time harming our youth? The current study draws from a nationwide sample of 11,875 participants in the United States, aged 9 to 10 years, from the Adolescent Brain Cognitive Development Study (ABCD Study&reg;). We investigate relationships between screen time and mental health, behavioral problems, academic performance, sleep habits, and peer relationships by conducting a series of correlation and regression analyses, controlling for SES and race/ethnicity. We find that more screen time is moderately associated with worse mental health, increased behavioral problems, decreased academic performance, and poorer sleep, but heightened quality of peer relationships. However, effect sizes associated with screen time and the various outcomes were modest; SES was more strongly associated with each outcome measure. Our analyses do not establish causality and the small effect sizes observed suggest that increased screen time is unlikely to be directly harmful to 9-and-10-year-old children. &nbsp;</p

The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence

MYC deregulation is common in human cancer. IG-MYC translocations that are modeled in EμMyc mice occur in almost all cases of Burkitt lymphoma as well as in other B-cell lymphoproliferative disorders. Deregulated expression of MYC results in increased mTOR complex 1 (mTORC1) signaling. As tumors with mTORC1 activation are sensitive to mTORC1 inhibition, we used everolimus, a potent and specific mTORC1 inhibitor, to test the requirement for mTORC1 in the initiation and maintenance of EμMyc lymphoma. Everolimus selectively cleared premalignant B cells from the bone marrow and spleen, restored a normal pattern of B-cell differentiation, and strongly protected against lymphoma development. Established EμMyc lymphoma also regressed after everolimus therapy. Therapeutic response correlated with a cellular senescence phenotype and induction of p53 activity. Therefore, mTORC1-dependent evasion of senescence is critical for cellular transformation and tumor maintenance by MYC in B lymphocytes

The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011–2018

Direct‐acting antiviral (DAA) therapy for anybody with viraemic HCV infection has been scaled‐up in England since 2017. To assess early impacts, we investigated trends in, and factors associated with, HCV viraemia among people who inject drugs (PWID). We also examined trends in self‐reported treatment access. Bio‐behavioural data from an annual, national surveillance survey of PWID (2011–2018) estimated trends in viraemic prevalence among HCV antibody‐positive PWID. Multivariable logistic regression identified characteristics independently associated with viraemia. Trends in treatment access were examined for PWID with known infection. Between 2011 and 2016, viraemic prevalence among antibody‐positive PWID remained stable (2011, 57.7%; 2016, 55.8%) but decreased in 2017 (49.4%) and 2018 (50.4%) (both p < 0.001). After adjustment for demographic and behavioural characteristics, there remained significant reduction in viraemia in 2017 (adjusted odds ratio [aOR] 0.79, 95% CI 0.65–0.94) and 2018 (aOR 0.79, 95% CI 0.66–0.93) compared to 2016. Other factors associated with viraemia were male gender (aOR 1.68, 95% CI 1.53–1.86), geographical region, injecting in past year (aOR 1.26, 95% CI 1.13–1.41), imprisonment (aOR 1.14, 95% CI 1.04–1.31) and homelessness (aOR 1.17, 95% CI 1.04–1.31). Among non‐viraemic PWID with known infection, the proportion reporting ever receiving treatment increased in 2017 (28.7%, p < 0.001) and 2018 (38.9%, p < 0.001) compared to 2016 (14.5%). In conclusion, there has been a small reduction in HCV viraemia among antibody‐positive PWID in England since 2016, alongside DAA scale‐up, and some indication that treatment access has improved in the same period. Population‐level monitoring and focus on harm reduction is critical for achieving and evaluating elimination

Cardiology providers’ recommendations for treatments and use of patient decision aids for multivessel coronary artery disease

Background: Rates of recommending percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) vary across clinicians. Whether clinicians agree on preferred treatment options for multivessel coronary artery disease patients has not been well studied. Methods and results: We distributed a survey to 104 clinicians from the Northern New England Cardiovascular Study Group through email and at a regional meeting with 88 (84.6%) responses. The survey described three clinical vignettes of multivessel coronary artery disease patients. For each patient vignette participants selected appropriate treatment options and whether they would use a patient decision aid. The likelihood of choosing PCI only or PCI/CABG over CABG only was modeled using a multinomial regression. Across all vignettes, participants selected CABG only as an appropriate treatment option 24.2% of the time, PCI only 25.4% of the time, and both CABG or PCI as appropriate treatment options 50.4% of the time. Surgeons were less likely to choose PCI over CABG (RR 0.14, 95% CI 0.03, 0.59) or both treatments over CABG only (RR 0.10, 95% CI 0.03, 0.34) relative to cardiologists. Overall, 65% of participants responded they would use a patient decision aid with each vignette. Conclusions: There is a lack of consensus on the appropriate treatment options across cardiologists and surgeons for patients with multivessel coronary artery disease. Treatment choice is influenced by both patient characteristics and clinician specialty